Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Transplant Proc ; 46(7): 2334-8, 2014 Sep.
Article in English | MEDLINE | ID: mdl-25242782

ABSTRACT

BACKGROUND: Proliferation signal inhibitors are increasingly used as immunosuppressive drugs in solid organ transplantation. Among their side effects peripheral lymphedema is rarely described in literature. METHODS: All heart transplant patients treated with everolimus (de novo or maintenance) at our center (135 patients: age 50.72±11.1 y, 115 male) were retrospectively analyzed. We considered the incidence of adverse events, particularly the appearance of peripheral edema (13 patients, 9.6%), and the correlation with preoperative characteristics, concomitant medications, other possible causes of edema, as well as all the measures developed for its therapeutic treatment. RESULTS AND CONCLUSIONS: Edema appearance, especially in lower limbs, was considered to be one of the most frequent side effects in heart transplant patients treated with everolimus. In some cases its regression was possible with an adjustment of drug dosages associated with diuretics and lymphatic drainage, but more often a suspension of the drug itself was required for complete regression of the symptoms.


Subject(s)
Heart Transplantation , Immunosuppressive Agents/adverse effects , Lymphedema/etiology , Sirolimus/analogs & derivatives , Everolimus , Female , Humans , Immunosuppressive Agents/administration & dosage , Incidence , Male , Middle Aged , Retrospective Studies , Sirolimus/administration & dosage , Sirolimus/adverse effects
2.
Transplant Proc ; 45(7): 2624-6, 2013 Sep.
Article in English | MEDLINE | ID: mdl-24034008

ABSTRACT

BACKGROUND: Among the strategies to increase the number of lung transplants, ex vivo lung perfusion (EVLP) represents a novel technique to expand the donor pool. METHODS: Data from donors referred to our center were retrospectively analyzed to identify grafts that could potentially be potentially reconditioned by EVLP and for comparison with those obtained by clinical application of EVLP program in our center. RESULTS: Among 75 rejected lungs, 23 organs have been identified as potentially treatable with EVLP with a hypothetic increase of lung transplant activity of 53%. After the introduction of the EVLP program in our center, lung transplantation with reconditioned grafts was performed in 7 (23%) patients with a 30% increase in transplant procedures. CONCLUSION: Although less than expected, EVLP increased the number of lungs suitable for transplantation.


Subject(s)
Lung Transplantation , Perfusion/methods , Humans , Tissue Donors
SELECTION OF CITATIONS
SEARCH DETAIL
...